Page 64 - 醫研部6月份電子報

Body weight gain of psoriasis patients after biologic use has been

observed. However, reports are inconsistent on whether biologic therapy

relates to body weight gain. The aim of the present study was to evaluate the

change in body weight and body mass index (BMI) of psoriasis patients after

various biologic treatments.

‣研究發現與應用

On March 1, 2019, we searched Medline, Embase, and Cochrane

Central Register of Controlled Trials for relevant studies. A network meta-

analysis was introduced because of the lack of direct comparisons between

anti-IL-12/ 23 or anti-IL-17 biologics and conventional therapy.

Six studies with 862 psoriasis patients were included. Compared with

conventional systemic treatments, treatment with tumor necrosis factor a

inhibitors was associated with a significant increase in body weight (mean

difference 1.40 kg, 95% confidence interval 0.88-1.93 kg) and BMI (0.39

kg/m2, 95% confidence interval 0.24-0.54 kg/m2). In contrast, no significant

increase in body weight or BMI was found among patients receiving anti-

interleukin (IL) 12/23 or anti-IL-17 biologics.

64